The originating document has been archived. We cannot confirm the completeness, accuracy, or currency of the content.
Infanrix HepB
Active Substance: diphtheria toxoid / tetanus toxoid / pertussis toxoid / pertussis haemagglutin filamentous / pertactin / hepatitis B recombinant surface antigen
Common Name: diphtheria, tetanus, acellular pertussis and hepatitis B recombinant, adsorbed vaccine
ATC Code: J07CA
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / tetanus toxoid / pertussis toxoid / pertussis haemagglutin filamentous / pertactin / hepatitis B recombinant surface antigen
Status: Withdrawn
Authorisation Date: 1997-07-30
Therapeutic Area: Hepatitis B
Diphtheria
Whooping Cough
Immunization
Tetanus
Pharmacotherapeutic Group: Vaccines
Therapeutic indication
Infanrix HepB is indicated for active immunisation of all infants from the age of 2 months against
diphtheria, tetanus, pertussis and hepatitis B.
The marketing authorisation for Infanrix HepB has been withdrawn at the request of the marketing authorisation holder.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.